Current Report Filing (8-k)
August 15 2022 - 5:29AM
Edgar (US Regulatory)
0001710340
false
0001710340
2022-08-10
2022-08-10
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
August
10, 2022
Date
of Report (Date of earliest event reported)
ETON
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-38738 |
|
37-1858472 |
(State
of incorporation) |
|
(Commission
File Number) |
|
(I.R.S. Employer
Identification Number) |
21925
W. Field Parkway, Suite 235
Deer
Park, Illinois 60010-7208
(Address
of principal executive offices) (Zip code)
(847)
787-7361
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock, par value $0.001 per share |
|
ETON |
|
NASDAQ
Global Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
8.01 Other Events.
Eton
was notified of a decision in the Paragraph IV litigation regarding cysteine hydrochloride injection. The court ruled to uphold Exela
Pharma Science’s patents. Eton strongly disagrees with the decision and expects Dr. Reddy’s Laboratories to appeal the ruling.
Eton sold the product to Dr. Reddy’s Laboratories in June 2022, and Dr. Reddy’s Laboratories is responsible for all legal
activities. Eton could still receive a milestone payment if Dr. Reddy’s Laboratories prevails on appeal and launches the product.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date:
August 12, 2022 |
By: |
/s/
James Gruber |
|
|
James
Gruber |
|
|
Chief
Financial Officer and Secretary |
|
|
(Principal
Financial Officer) |
Eton Pharmaceuticals (NASDAQ:ETON)
Historical Stock Chart
From Apr 2024 to May 2024
Eton Pharmaceuticals (NASDAQ:ETON)
Historical Stock Chart
From May 2023 to May 2024